Abstract
The rise in antimicrobial resistance poses a worldwide threat, reducing the efficacy of common antibiotics. Determining the antimicrobial activity of new chemical compounds through experimental methods is still a time-consuming and costly endeavor. Compound-centric deep learning models hold the promise to speed up this search and prioritization process. Here, we introduce a lightweight computational strategy for antimicrobial discovery that builds on MolE(Molecular representation through redundancy reduced Embedding), a deep learning framework that leverages unlabeled chemical structures to learn task-independent molecular representations. By combining MolE representation learning with experimentally validated compound-bacteria activity data, we design a general predictive model that enables assessing compounds with respect to their antimicrobial potential. The model correctly identified recent growth-inhibitory compounds that are structurally distinct from current antibiotics and discovered de novo three human-targeted drugs as Staphylococcus aureus growth inhibitors which we experimentally confirmed. Our framework offers a viable cost-effective strategy to accelerate antibiotics discovery.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Updated overall figures and text. Results are unchanged, formatting and extended data now in the main manuscript file